QuantuMDx - Changing healthcare, Globally

QuantuMDx Group Logo

QuantuMDx Management Team

Our Management Team

Elaine Warburton OBE | Chief Executive Officer

Elaine Warburton OBE25 years’ experience in healthcare/hospital management introducing new technologies into mainstream medicine. Serial entrepreneur; raised over £25m in angel, grant and VC investment.

Prof. Sir John Burn | Chairman

Professor Sir John Burn, ChairmanProfessor of Clinical Genetics, Board Member of NHS England with special focus on genomics, Genetics Chair, UK NIHR, Honorary Consultant Clinical Geneticist.

Jonathan O'Halloran | Chief Scientific Officer

Jonathan O'Halloran, Chief Scientific OfficerInventor of QuantuMDx’s proprietary nucleic acid preparation, amplification and detection technology with over 12 years in scientific research, biotechnology & clinical laboratories.

Julian Warburton | Chief Finance Officer

Julian Warburton, Chief Finance Officer25 years’ experience in Corporate Finance, Banking and Treasury Risk Management for FTSE 100/250 companies including ICI, Diageo, Willis, Intertek and HSBC.

Sam Whitehouse | Chief Operating Officer

Sam Whitehouse, Chief Operating OfficerInventor of underlying DNA extraction chemistries. 12 years biotech experience including industrial research and managing a large portfolio of academic-industry biotech collaborations.

Non-Exec. Director & President, USA

Paul J. Fitzpatrick, President, QuantuMDx USA 25 years’ experience in healthcare & medical device commercialisation from early stage, 20 M&A transactions; raised over $30m in private equity & VC financings.

The company engages with a large number of independent scientific, medical and commercial advisors to support every aspect of its operations. The company's technology has been extensively peer reviewed.

QuantuMDx DevicesQuantuMDx investment opportunitiesQuantuMDx Mission StatementQuanutMDx bio technololgyQuantuMDx developing new assays